Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for liver cancer: Triple-Drug combo trial launches

NCT ID NCT07219459

Recruiting now Disease control Sponsor: CatalYm GmbH Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 22, 2026 · Updated 2 times

Summary

This phase 2b trial tests whether adding visugromab and nivolumab to standard lenvatinib can help people with advanced liver cancer that has worsened after initial treatment. About 104 participants will receive either the triple combination or a placebo plus lenvatinib. The study aims to see if the new combo slows cancer growth.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
visugromab (CTL-002) combined with nivolumab and lenvatinib
What this could lead to
If successful, this combination could offer a new treatment option for people with advanced liver cancer who have stopped responding to initial therapy.
What could go wrong
This is a mid-stage trial with only 104 participants, so results may not apply to everyone. The added drugs may increase side effects without improving outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHILD-PUGH A HEPATOCELLULAR CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHILD-PUGH A HEPATOCELLULAR CARCINOMA FAILURE OF FIRST-LINE TREATMENT THAT INCLUDED AN ANTI PD-(L)1 COMPOUND FAILURE OF FIRST-LINE TREATMENT THAT INCLUDED AN APPROVED ANTI PD-(L)1 COMPOUND UNRESECTABLE OR METASTATIC HEPATOCELLULAR CARCINOMA

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Asst Grande Ospedale Metropolitano Niguarda

    RECRUITING

    Milan, 20162, Italy

    Contact Email: •••••@•••••

  • Catalan Institute of Oncology, Hospital Duran i Reynals

    RECRUITING

    L'Hospitalet de Llobregat, Barcelona, 08908, Spain

  • Hannover Medical School

    RECRUITING

    Hanover, Lower Saxony, 30625, Germany

  • Hospital Clinic of Barcelona

    RECRUITING

    Barcelona, Catalonia, 08036, Spain

  • OSF St. Francis Medical Center

    RECRUITING

    Peoria, Illinois, 61637, United States

  • Ospedale S.Maria delle Croci

    RECRUITING

    Ravenna, 48121, Italy

  • Peidmont Healthcare, Inc

    RECRUITING

    Atlanta, Georgia, 30309, United States

  • Polyclinic S. Orsola-Malpighi

    RECRUITING

    Bologna, 40138, Italy

  • USC Norris Comprehensive Cancer Center

    RECRUITING

    Los Angeles, California, 90033, United States

  • University Clinic of Navarra - Pamplona

    RECRUITING

    Pamplona, Chartered Community of Navarra, 31008, Spain

  • University Hospital Miguel Servet

    RECRUITING

    Zaragoza, Aragon, 50009, Spain

  • University Hospital Ramon y Cajal

    RECRUITING

    Madrid, Madrid, 28034, Spain

  • University Medical Center of Johannes Gutenberg University Mainz

    RECRUITING

    Mainz, Rhineland-Palatinate, 55131, Germany

  • Universitätsklinikum Frankfurt Johann Wolfgang Goethe- Universität

    RECRUITING

    Frankfurt, 60590, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.